What Ali Raif Pharmaceutical does

Ali Raif Pharmaceutical (Ali Raif İlaç Sanayi A.Ş.) is a 100% Turkish-domestic capital pharmaceutical manufacturer and marketer headquartered in Kağıthane, Istanbul. Originally founded in 1928 and reorganized in 1963 for pharmaceutical operations, the company today operates a portfolio of 205 active licensed products spanning cardiology, psychiatry, neurology, hematology, gastroenterology, diabetes, physical therapy/rheumatology, MS, and oncology. Products are manufactured at a GMP-compliant facility in the İkitelli Organized Industrial Zone (with a new production facility under construction since 2020), supplemented by 22 imported products including medical devices such as BabySpasmyl (in partnership with France's Mayoly Spindler). The company also operates the ARİS Life sub-brand for consumer health products (sweeteners, dietary supplements, Class I/IIA medical devices).

The company runs a Ministry of Industry and Technology-certified R&D Center (Ar-Ge Merkezi, certified 2 January 2017) with a 25-person multidisciplinary team (pharmacists, chemical engineers, chemists) — 70% female — that registered 96 trademarks in 2024 and ranks 1st nationally in TurkishTime's R&D 250 Research 2023 for trademark output from an R&D Center. R&D spend is approximately 3% of revenue.

Commercially, Ali Raif uses a field-sales GTM motion: medical sales representatives target physicians and specialists across 12 regional offices covering Istanbul, Bursa, Ankara, Izmir, Antalya, Samsun, Adana, Diyarbakir, and Trabzon, with products distributed through retail pharmacies and hospital procurement under TITCK pricing and SGK reimbursement regulation. Scientific partnerships with the Turkish Cardiology Society, Türkiye Fiziksel Tıp ve Rehabilitasyon Derneği, and thalassemia patient associations underpin category authority. The company is ranked 21st among 452 firms in the Turkish pharmaceutical market, with 850+ employees and 60+ years of operating heritage.

Name

Ali Raif Pharmaceutical

Legal name

Ali Raif İlaç Sanayi A.Ş.

Website

https://aliraif.com.tr

Company type

Private

Founded year

1928

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Generic pharmaceutical manufacturing
• Branded pharmaceutical products
• Pharmaceutical research development
• Medical device marketing
• Dietary supplements production

Headquarters

HQ city

Kagithane

Offices12 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Ali Raif İlaç generates revenue primarily through the sale of pharmaceutical products including branded generic drugs. The company has 205 active licensed products in its portfolio covering multiple therapeutic areas including cardiology, psychiatry, neurology, hematology, gastroenterology, diabetes, and more. Products are sold through pharmacies and hospitals across Turkey.
2. Medical Device Sales: The company also markets medical devices including Class 1 and Class 2A medical devices under the Aris Life brand.
3. Dietary Supplement Products: Sale of dietary supplements and traditional herbal medicinal products under the consumer health category.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Ali Raif İlaç is a 100% Turkish-capital pharmaceutical manufacturer and marketer operating a portfolio of 205 licensed branded-generic and imported products across cardiology, psychiatry, neurology, hematology, gastroenterology, diabetes, multiple sclerosis, physical therapy/rheumatology, and oncology. The company produces most of its portfolio at a GMP-certified facility in İkitelli, Istanbul, and complements pharmaceuticals with the ARİS Life sub-brand of medical devices, dietary supplements, and sweeteners.

Product overview

Ali Raif İlaç is a 100% domestic-capital Turkish pharmaceutical company established in 1928, operating 205 licensed products with manufacturing facilities in İkitelli, Istanbul. The company follows a platform-plus-modules architecture with core pharmaceutical products across multiple therapeutic areas (cardiology, gastroenterology, psychiatry/neurology, hematology, MS, oncology, physical therapy/rheumatology) supported by the Aris Life sub-brand for consumer health products including medical devices, dietary supplements, and sweeteners. The company develops and manufactures products at its own GMP-compliant facilities while also importing 22 products. Key therapeutic areas include cardiology with 60+ years experience, psychiatry/neurology with 40+ years, and gastroenterology with 50+ years of expertise.

Differentiator

Problem solved

Functional benefit

Brands

• ARİS Life: Sub-brand covering sweeteners, dietary supplements, and medical devices product categories.

Products and services

• Ali Raif İlaç Pharmaceutical Portfolio Branded generic and imported pharmaceutical product portfolio of 205 licensed products (including 22 imported) covering multiple therapeutic areas; manufactured at Ali Raif's GMP-compliant İkitelli facility and sold through retail pharmacies and hospitals in Turkey.
• Deferasirox Product Iron chelation therapy containing deferasirox active ingredient for treatment of chronic iron overload from blood transfusions and non-transfusion-dependent thalassemia syndromes; targeted at hematology specialists and patients aged 10 and over.
• BabySpasmyl Imported Class I/Class IIA medical device in drop form for infant colic, gas, bloating, and aerophagia; launched in partnership with French company Mayoly Spindler.
• Antidepressant and Antipsychotic Combination Brand Psychiatric medication combining antidepressant and antipsychotic properties, developed with 44 years of clinical experience in psychiatry and neurology; winner of the 15th Altın Havan Innovative Product of the Year Award (2026).
• Cardiology Product Portfolio Comprehensive cardiology branded generic range for heart failure, anticoagulants, hyperlipidemia, and antihypertensives, supported by 60+ years of cardiovascular expertise and two dedicated cardiology teams.
• MS Product Portfolio Multiple Sclerosis treatment products with a dedicated MS team established in January 2021, representing one of the fastest-growing segments of the company.
• ARİS Life Sub-Brand Portfolio Sub-brand covering sweeteners, dietary supplements, and Class I/IIA medical devices such as BabySpasmyl, expanding Ali Raif into consumer health products.

Quantifiable outcome

• Ranked 1st in Turkey for trademark registrations from R&D Center (Turkishtime R&D 250 Research 2023)
• +4 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

16 partnerships are on record, tiered core and minor.

• Kimyagerler Derneği ve Atatürk ÜniversitesicoreStrategic or Co-development Partner · 1 March 2026Partnership for 14th International Pharmaceutical Chemistry Congress and Crystal Mortar Awards. Ali Raif presented research poster and received 3rd place award for 96 trademarks registered at R&D Center in 2024.
• Brandon Hall GroupcoreStrategic or Co-development Partner · 1 September 2025International recognition for innovative employee development approach. Ali Raif received Bronze Award at 2025 Brandon Hall Group HCM Excellence Awards.
• Stevie AwardscoreStrategic or Co-development Partner · 1 September 2025International business awards recognizing innovative HR practices. Ali Raif received Bronze award for employee development and young talent programs at Stevie Awards 2025.
• Sağlık Bilimleri Üniversitesi İstanbul Haseki Eğitim ve Araştırma HastanesicoreStrategic or Co-development Partner · 1 September 2025Scientific collaboration for 'Doğru Bilinen Yanlışlar - Kalp Sağlığı' project. Prof. Dr. Erdal Belen provided scientific consultancy for heart health awareness initiative combining humor with scientific information.
• Ege Orman VakfıminorOthers · 1 January 2025Environmental partnership for memorial forest projects. Ali Raif created 5,680-tree '14 Mart Hatıra Ormanı' in Sakarya Hendek through this partnership.
• DarüşşafakaminorOthers · 1 January 2024Charitable partnership through Istanbul Marathon. Support for education of orphans through quality education opportunities.
• KAÇUV (Kanserli Çocuklara Umut Vakfı)minorOthers · 1 January 2024Charitable partnership through Istanbul Marathon. Support for healthcare capacity providing appropriate treatment access for children with cancer.
• UCİM (Saadet Öğretmen Çocuk İstismarı ile Mücadele Derneği)minorOthers · 1 January 2024Charitable partnership through Istanbul Marathon. Support for protecting children from physical, emotional abuse and neglect.
• Türkiye Eğitim ve Gelişim Platformu Derneği (TEGEP)coreStrategic or Co-development Partner · 1 January 2022Partnership for TEGEP Öğrenme ve Gelişim Ödülleri. Ali Raif won Bronze award for 'Aris Future Gelişim Yolculuğu' talent development program with 75% participant promotion rate.
• TİTCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu)coreOthers · 1 January 2021Regulatory partnership for drug registration, pricing, and market access. Ali Raif works with TİTCK for product licensing and compliance.
• SGK (Sosyal Güvenlik Kurumu)coreOthers · 1 January 2021Reimbursement partnership for drug pricing and social security coverage. Ali Raif products are included in SGK reimbursement list for patient access.
• Kariyer.netcoreStrategic or Co-development Partner · 1 January 2019HR partnership for Respect for Human Awards. Ali Raif consistently recognized for candidate experience (99.8% response rate, 30,000 applications, 79 hires).
• Talasemi ve Kan Bağışı DerneklericoreStrategic or Co-development Partner · 1 January 2019Partnership for 'Kan Candır' blood donation awareness project. Collaboration with patient associations to raise awareness about thalassemia and increase blood donations.
• Türk Kardiyoloji DerneğicoreStrategic or Co-development Partner · 1 January 2018Long-standing partnership with Turkish Cardiology Society (both founded 1963). Ali Raif is the only local pharmaceutical company in TKD Industry Relations Project Group, collaborating on cardiology standards and projects.
• Türkiye Fiziksel Tıp ve Rehabilitasyon DerneğicoreStrategic or Co-development Partner · 1 January 2018Collaboration for Fibromyalgia Awareness Day press conference. Dernek Başkanı Prof. Dr. Ayşegül Ketenci and other executives provided expert presentations on fibromyalgia treatment and nutrition.
• Mayoly SpindlercoreTechnology or Integration · 1 January 2018French pharmaceutical partnership for BabySpasmyl - medical device for infant digestive disorders. Leveraging 20+ years of gastroenterology experience in Turkey.

Scale indicators15 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Sandoz Turkey: Turkish subsidiary of Sandoz, the global generics leader. Comparable as a branded generic competitor in the same Turkish market with broader international backing and larger R&D resources.
• AstraZeneca Turkey: Turkish subsidiary of global biopharmaceutical major with strong cardiology franchise. Competes with Ali Raif's cardiology portfolio (the company's longest-standing therapeutic area) from a multinational position with greater R&D funding.
• Sanofi Turkey: Turkish subsidiary of global pharmaceutical major Sanofi. Competes with Ali Raif across multiple therapy areas with much larger scale, deeper R&D resources, and stronger SGK negotiation leverage.
• Recordati İlaç (Turkey): Turkish operations of Recordati, a European specialty pharma group with significant presence in cardiovascular and urology. Overlaps with Ali Raif's cardiology franchise while operating as part of a broader international portfolio.

Direct peers

• Nobel İlaç: Major Turkish pharmaceutical manufacturer with a broad portfolio spanning cardiovascular, CNS, and gastroenterology. Comparable to Ali Raif in business model, therapeutic focus, and domestic manufacturing footprint.
• Biofarma İlaç: Turkish pharmaceutical manufacturer focused on branded generics. Comparable to Ali Raif in therapeutic breadth, manufacturing approach, and target customer base (physicians and pharmacists in Turkey).
• Deva Holding: Turkish pharmaceutical manufacturer with strong presence across multiple therapeutic areas including cardiology and CNS. Competes directly with Ali Raif in the domestic branded generics market with similar field-sales-driven commercial model.
• Bilim İlaç: Turkish pharmaceutical manufacturer with branded generic focus across multiple therapy areas. Directly comparable to Ali Raif in scale, business model, and Turkish-market-only positioning.
• Abdi İbrahim: Turkey's largest domestic pharmaceutical company, headquartered in Istanbul. Directly comparable to Ali Raif as a Turkish-capital pharma manufacturer with a broad multi-therapeutic portfolio and R&D investment, though significantly larger in scale and market share.
• Eczacıbaşı (EIP): Turkish conglomerate's pharmaceutical division operating in branded generics and consumer health. Comparable to Ali Raif in domestic capital structure, multi-therapeutic portfolio, and field-sales-driven model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/aliraifilacsan
• YouTubeyoutube.com/channel/UCaFaxJFH7oXzYoO6lUe44_w
• Facebookfacebook.com/aliraifilac
• LinkedInlinkedin.com/company/aliraifilac
• Instagraminstagram.com/aliraifilac

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ali Raif Pharmaceutical